ArticleProceedings of the National Academy of Sciences of the United States of America2017
Internalized CD44s splice isoform attenuates EGFR degradation by targeting Rab7A.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Immune-associated alternative splicing signatures define molecular subtypes in breast cancer.iScience · 2026Article
- Extracellular matrix mediates circulating tumor cell clustering in triple-negative breast cancer metastasis.Nature communications · 2026Article
- HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway.Journal of cellular and molecular medicine · 2025Article
- Review
- A method for in silico exploration of potential glioblastoma multiforme attractors using single-cell RNA sequencing.Scientific reports · 2024Article
- The role of Golgi complex proteins in cell division and consequences of their dysregulation.Frontiers in cell and developmental biology · 2024Review
- Endosomal Arl4A attenuates EGFR degradation by binding to the ESCRT-II component VPS36.Nature communications · 2023Article
- CD44 Intracellular Domain: A Long Tale of a Short Tail.Cancers · 2023Review
- Collagen I-DDR1 signaling promotes hepatocellular carcinoma cell stemness via Hippo signaling repression.Cell death and differentiation · 2023Article
- Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance.International journal of molecular sciences · 2022Review
- Endocytic trafficking of GAS6-AXL complexes is associated with sustained AKT activation.Cellular and molecular life sciences : CMLS · 2022Article
- ChGn-2 Plays a Cardioprotective Role in Heart Failure Caused by Acute Pressure Overload.Journal of the American Heart Association · 2022Article
- Lipid droplets and ferroptosis as new players in brain cancer glioblastoma progression and therapeutic resistance.Frontiers in oncology · 2022Review
- CD44: A Multifunctional Mediator of Cancer Progression.Biomolecules · 2021Review
- Rolling-translated EGFR variants sustain EGFR signaling and promote glioblastoma tumorigenicity.Neuro-oncology · 2021Article
- TRIM39 deficiency inhibits tumor progression and autophagic flux in colorectal cancer via suppressing the activity of Rab7.Cell death & disease · 2021Article
- The Stemness-High Human Colorectal Cancer Cells Promote Angiogenesis by Producing Higher Amounts of Angiogenic Cytokines via Activation of the Egfr/Akt/Nf-κB Pathway.International journal of molecular sciences · 2021Article
- The impact of molecular tumor profiling on the design strategies for targeting myeloid leukemia and EGFR/CD44-positive solid tumors.Beilstein journal of nanotechnology · 2021Review
- EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.Theranostics · 2021Article
- CD44/HA signaling mediates acquired resistance to a PI3Kα inhibitor.Cell death & disease · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
CD44 has been postulated as a cell surface coreceptor for augmenting receptor tyrosine kinase (RTK) signaling. However, how exactly CD44 triggers RTK-dependent signaling remained largely unclear. Here we report an unexpected mechanism by which the CD44s splice isoform is internalized into endosomes to attenuate EGFR degradation. We identify a CD44s-interacting small GTPase, Rab7A, and show that CD44s inhibits Rab7A-mediated EGFR trafficking to lysosomes and subsequent degradation. Importantly, CD44s levels correlate with EGFR signature and predict poor prognosis in glioblastomas. Because Rab7A facilitates trafficking of many RTKs to lysosomes, our findings identify CD44s as a Rab7A regulator to attenuate RTK degradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.